日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity

LILRB2阻断可促进巨噬细胞重极化并增强T细胞介导的抗肿瘤免疫

Jones, Des C; Irving, Lorraine; Dudley, Rebecca; Blümli, Seraina; Wolny, Marcin; Chatzopoulou, Elisavet I; Pryts, Stacy; Ahuja, Shreya; Rees, D Gareth; Sandercock, Alan M; Rajan, Saravanan; Varkey, Reena; Kierny, Michael; Kayserian, Andrew; Mulgrew, Kathy; Bowyer, Georgina; Songvilay, Saly; Bienkowska, Kamila; Glover, Matthew S; Hess, Sonja; Dovedi, Simon J; Wilkinson, Robert W; Arnaldez, Fernanda; Cobbold, Mark

Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors

一项针对晚期实体瘤患者的重组减毒溶瘤病毒 MEDI5395 (NDV-GM-CSF) 的 I 期研究,该病毒采用全身给药方式与度伐利尤单抗联合给药。

Davar, Diwakar; Carneiro, Benedito A; Dy, Grace K; Sheth, Siddharth; Borad, Mitesh J; Harrington, Kevin J; Patel, Sandip P; Galanis, Evanthia; Samson, Adel; Agrawal, Sonia; Chen, Zhongying; Fan, Chunling; Gong, Maozhen; Burton, Jenny; Tu, Eric; Durham, Nicholas; Laubscher, Kevin; Arnaldez, Fernanda; Zamarin, Dmitriy

Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Palbociclib (PD-0332991) 治疗 CCND1、2 或 3 扩增的 II 期研究:NCI-MATCH ECOG-ACRIN 试验 (EAY131) 子方案 Z1B 的结果

Clark, Amy S; Hong, Fangxin; Finn, Richard S; DeMichele, Angela M; Mitchell, Edith P; Zwiebel, James; Arnaldez, Fernanda I; Gray, Robert J; Wang, Victoria; McShane, Lisa M; Rubinstein, Larry V; Patton, David; Williams, P Mickey; Hamilton, Stanley R; Copur, Mehmet S; Kasbari, Samer S; Thind, Ravneet; Conley, Barbara A; Arteaga, Carlos L; O'Dwyer, Peter J; Harris, Lyndsay N; Chen, Alice P; Flaherty, Keith T

A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma

一项针对患有SDH缺陷型胃肠道间质瘤、嗜铬细胞瘤、副神经节瘤和HLRCC相关肾细胞癌的儿童和成人患者的Guadecitabine II期临床试验

Ligon, John A; Sundby, R Taylor; Wedekind, Mary F; Arnaldez, Fernanda I; Del Rivero, Jaydira; Wiener, Lori; Srinivasan, Ramaprasad; Spencer, Melissa; Carbonell, Amanda; Lei, Haiyan; Shern, John; Steinberg, Seth M; Figg, William D; Peer, Cody J; Zimmerman, Sara; Moraly, Josquin; Xu, Xia; Fox, Stephen; Chan, King; Barbato, Michael I; Andresson, Thorkell; Taylor, Naomi; Pacak, Karel; Killian, J Keith; Dombi, Eva; Linehan, W Marston; Miettinen, Markku; Piekarz, Richard; Helman, Lee J; Meltzer, Paul; Widemann, Brigitte; Glod, John

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

依诺妥珠单抗联合帕博利珠单抗双重靶向B7-H3和PD-1治疗晚期实体瘤:一项多中心I/II期试验的中期结果

Aggarwal, Charu; Prawira, Amy; Antonia, Scott; Rahma, Osama; Tolcher, Anthony; Cohen, Roger B; Lou, Yanyan; Hauke, Ralph; Vogelzang, Nicholas; P Zandberg, Dan; Kalebasty, Arash Rezazadeh; Atkinson, Victoria; Adjei, Alex A; Seetharam, Mahesh; Birnbaum, Ariel; Weickhardt, Andrew; Ganju, Vinod; Joshua, Anthony M; Cavallo, Rosetta; Peng, Linda; Zhang, Xiaoyu; Kaul, Sanjeev; Baughman, Jan; Bonvini, Ezio; Moore, Paul A; Goldberg, Stacie M; Arnaldez, Fernanda I; Ferris, Robert L; Lakhani, Nehal J

Role of Fcγ receptors in HER2-targeted breast cancer therapy

Fcγ受体在HER2靶向乳腺癌治疗中的作用

Musolino, Antonino; Gradishar, William J; Rugo, Hope S; Nordstrom, Jeffrey L; Rock, Edwin P; Arnaldez, Fernanda; Pegram, Mark D

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group

临床试验入组标准现代化:ASCO-癌症研究之友体能状态工作组的建议

Magnuson, Allison; Bruinooge, Suanna S; Singh, Harpreet; Wilner, Keith D; Jalal, Shadia; Lichtman, Stuart M; Kluetz, Paul G; Lyman, Gary H; Klepin, Heidi D; Fleury, Mark E; Hirsch, Brad; Melemed, Allen; Arnaldez, Fernanda I; Basu Roy, Upal; Schenkel, Caroline; Sherwood, Shimere; Garrett-Mayer, Elizabeth

The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response

癌症免疫治疗学会对 COVID-19 相关全身炎症反应中白细胞介素-6 信号通路调控的观点

Arnaldez, Fernanda I; O'Day, Steven J; Drake, Charles G; Fox, Bernard A; Fu, Bingqing; Urba, Walter J; Montesarchio, Vincenzo; Weber, Jeffrey S; Wei, Haiming; Wigginton, Jon M; Ascierto, Paolo Antonio

MON-388 To Cut Or Not To Cut? Cystic Adrenal Lymphangioma Mimicking Pheochromocytoma

MON-388 切除还是不切除?囊性肾上腺淋巴管瘤酷似嗜铬细胞瘤

Rees, Matthew G; Seashore-Ludlow, Brinton; Clemons, Paul A; Harty, Roger; Thomas, BJ; Fuller, Sarah; Ilanchezhian, Maran; Allen, Deborah; Allen, Taryn; Weiner, Lori; Wisch, Laura; Sherri, DePollar; Gillespie, Andy; Raygada, Margarita; Arnaldez, Fernanda; Reilly, Karlyne; Glod, John; Widemann, Brigitte; Del Rivero, Jaydira; Lee, Christine; Tan, Marilyn; Ziganshina, Anna; Ostapenko, Alexandr; Nguyen, Quoc; Mones, Laura; Liechty, Shawn; Lamas, Marcos; Kleiner, Daniel

Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma

基质筛选确定了 PARP 抑制剂和烟酰胺磷酸核糖转移酶 (NAMPT) 抑制剂在尤文氏肉瘤中的协同作用

Christine M Heske, Mindy I Davis, Joshua T Baumgart, Kelli Wilson, Michael V Gormally, Lu Chen, Xiaohu Zhang, Michele Ceribelli, Damien Y Duveau, Rajarshi Guha, Marc Ferrer, Fernanda I Arnaldez, Jiuping Ji, Huong-Lan Tran, Yiping Zhang, Arnulfo Mendoza, Lee J Helman, Craig J Thomas